Targeting TRAF3IP2 by Genetic and Interventional Approaches Inhibits Ischemia/Reperfusion-induced Myocardial Injury and Adverse Remodeling*

John M. Erikson1, Anthony J. Valente2, Srinivas Mummid2, Hemanth Kumar Kandikattu3, Vincent G. DeMarco4**, Shawn B. Bender3,4†‡, William P. Fay4†, Ulrich Siebenlist3,§§ and Bysani Chandrasekar†,§¶

From the 1Department of Medicine, University of Texas Health Science Center, San Antonio, Texas 78229, the 2Department of Medicine, University of Missouri School of Medicine, Columbia, Missouri 65211, the 3Research Service, Harry S. Truman Memorial Veterans Hospital, Columbia, Missouri 65201, the Departments of 4Medical Pharmacology and Physiology and 5Biomedical Sciences, University of Missouri School of Medicine, Columbia, Missouri 65211, and the 6Laboratory of Immunoregulation, NIAID, National Institutes of Health, Bethesda, Maryland 20892

Edited by Dennis R. Voelker

Re-establishing blood supply is the primary goal for reducing myocardial injury in subjects with ischemic heart disease. Paradoxically, reperfusion results in nitrosative stress and a marked inflammatory response in the heart. TRAF3IP2 (TRAF3 Interacting Protein 2; previously known as CIKS or Act1) is an oxidative stress-responsive cytoplasmic adapter molecule that is an upstream regulator of both IκB kinase (IKK) and c-Jun N-terminal kinase (JNK), and an important mediator of autoimmune and inflammatory responses. Here we investigated the role of TRAF3IP2 in ischemia/reperfusion (I/R)-induced nitrosative stress, inflammation, myocardial dysfunction, injury, and adverse remodeling. Our data show that I/R up-regulates TRAF3IP2 expression in the heart, and its gene deletion, in a conditional cardiomyocyte-specific manner, significantly attenuates I/R-induced nitrosative stress, IKK/NF-κB and JNK/AP-1 activation, inflammatory cytokine, chemokine, and adhesion molecule expression, immune cell infiltration, myocardial injury, and contractile dysfunction. Furthermore, Traf3ip2 gene deletion blunts adverse remodeling 12 weeks post-I/R, as evidenced by reduced hypertrophy, fibrosis, and contractile dysfunction. Supporting the genetic approach, an interventional approach using ultrasound-targeted microbubble destruction-mediated delivery of phosphorothioated TRAF3IP2 antisense oligonucleotides into the LV in a clinically relevant time frame significantly inhibits TRAF3IP2 expression and myocardial injury in wild type mice post-I/R. Furthermore, ameliorating myocardial damage by targeting TRAF3IP2 appears to be more effective to inhibiting its downstream signaling intermediates NF-κB and JNK. Therefore, TRAF3IP2 could be a potential therapeutic target in ischemic heart disease.

Ischemic heart disease is a leading cause of morbidity and mortality worldwide (1). Although reperfusion of the ischemic myocardium is the primary goal of reducing myocardial injury and dysfunction, paradoxically it can also produce pathological effects by the (i) excessive generation of reactive oxygen and nitrogen species, (ii) activation of the redox-sensitive dimeric transcription factors NF-κB and AP-1, (iii) up-regulation of inflammatory mediators, (iv) recruitment and activation of immune and inflammatory cells, and (v) induction of cardiomyocyte apoptosis, which ultimately results in myocardial injury, dysfunction (ischemia/reperfusion injury or I/R injury), and adverse remodeling (2, 3). Despite progress in our understanding of its underlying molecular mechanisms, myocardial injury post-I/R remains an important clinical problem.

A number of studies have firmly established causal roles for the nuclear transcription factors NF-κB and AP-1 in myocardial I/R injury (4–12). Various stimuli, including oxidative stress, cytokines, and growth factors, activate NF-κB by inducing the hyperphosphorylation and degradation of its inhibitory subunit IκB. A multiprotein complex comprised of IKKα, IKKβ, and a regulatory subunit IKKγ/NEMO was shown to mediate phosphorylation of IκB, followed by ubiquitination and degradation, resulting in NF-κB activation, nuclear translocation, and gene induction (4, 13, 14).

Like NF-κB, AP-1 is a highly inducible redox-sensitive nuclear transcription factor. It is composed mainly of Jun and Fos subunits. Phosphorylation of c-Jun by JNK results in nuclear translocation and transcriptional up-regulation of...
TRAF3IP2 in Ischemic Heart Disease

AP-1-dependent inflammatory and apoptotic gene expression. Of note, ischemia/reperfusion (I/R),5 but not ischemia alone, activates JNK (10). Similar to inhibition of IKK and NF-κB, jnk gene deletion or inhibition attenuates I/R-induced cardiomyocyte death (11, 12). These reports demonstrate that activation of NF-κB or AP-1 is detrimental, and suggest that targeting their expression or activation is cardioprotective in myocardial I/R injury.

The cytoplasmic adapter molecule TRAF3IP2 mediates the activation of both NF-κB and AP-1 (15, 16). Although TRAF3IP2 physically associates with IKK and activates NF-κB (15), we have previously demonstrated that its physical interaction with IKKγ results in JNK activation in cardiomyocytes (17), suggesting that induction of TRAF3IP2 could result in activation of proinflammatory signal transduction pathways regulated by both IKK/NF-κB and JNK/AP-1.

Similar to NF-κB and AP-1, TRAF3IP2 is a highly inducible redox-sensitive adapter molecule. Its promoter region contains potential binding sites for AP-1, NF-κB, C/EBPβ, CREB, and IRF1 (18, 19), indicating that oxidative stress induces TRAF3IP2 expression, and upon induction, it may regulate its own expression and that of multiple inflammatory mediators, ultimately resulting in tissue injury and dysfunction. In fact, we have previously demonstrated that advanced oxidation protein products, which serve as markers of oxidative stress and mediators of inflammation, induce cardiomyocyte death in part via Nox2/Rac1/superoxide-dependent TRAF3IP2/JNK signaling (20). Its pathological role is also demonstrated in various autoimmune and inflammatory diseases (21, 22). However, it is not known whether TRAF3IP2 plays a causal role in myocardial I/R injury. Using both genetic (conditional cardiomyocyte-specific Traf3ip2 gene deletion) and interventional (ultrasound-targeted microbubble destruction (UTMD)-mediated delivery of phosphorothioated TRAF3IP2 antisense oligonucleotides into the LV chamber) approaches, we report for the first time that TRAF3IP2 plays a causal role in myocardial I/R injury, dysfunction, and adverse remodeling. We also determined that TRAF3IP2 might be a better therapeutic target than either NF-κB or JNK alone in reducing myocardial injury post-I/R.

Results

I/R Induces TRAF3IP2 Expression in the Heart—Previously, we demonstrated that 30-min ischemia/2-h reperfusion induces oxidative stress and activation of the oxidative stress-responsive transcription factors NF-κB and AP-1 in the heart (23–26). Because TRAF3IP2 is an oxidative stress-responsive cytoplasmic adapter molecule and upstream regulator of NF-κB and AP-1 (15, 16), we hypothesized that I/R will induce TRAF3IP2 expression in the heart. Wild type mice underwent 30-min ischemia/2-h reperfusion (Fig. 1A), and TRAF3IP2 expression was analyzed by immunoblotting. The level of TRAF3IP2 expressed in the myocardium of wild type mice was not significantly altered by either sham surgery (Fig. 1A), or treatment with ischemia alone (Fig. 1B). However, TRAF3IP2 expression was markedly up-regulated in a time-dependent manner in the heart post-I/R (Fig. 1B). Although increased expression was observed as early as 30 min after reperfusion, its levels increased further at 2 h reperfusion, and remained elevated even at 6 h reperfusion (Fig. 1B). Immunohistochemistry revealed that TRAF3IP2 is present in cardiomyocytes localized to cytoplasm and membranes, and I/R increased its expression specifically in the ischemic (Is) zone (Fig. 1C). Confirming our hypothesis, these results indicate that I/R up-regulates TRAF3IP2 expression in the heart (Fig. 1).

Conditional Cardiomyocyte-specific Traf3ip2 Gene Deletion Inhibits I/R-induced Nitrooxidative Stress, Inflammatory Response, Myocardial Dysfunction, Injury, and Adverse Remodeling—

5 The abbreviations used are: I/R, ischemia/reperfusion; ALT, alanine transaminase; AS-ODN, antisense oligonucleotides; AST, aspartate transaminase; C/EBPβ, CCAAT enhancer-binding protein; CREB, cAMP responsive element-binding protein 1; IRF, interferon regulatory factor; LFA, lymphocyte function-associated antigen; LIX, lipopolysaccharide-induced CXC chemokine; NEMO, NF-κB essential modulator; TCC, triptolides; TTC, 2,3,5-triphenyltetrazolium chloride; UTMD, ultrasound-targeted microbubble destruction; CM-KO, cardiomyocyte knock-out; F5, fractional shortening; PESDA, perfluorocarbon-exposed sonicated dextran albumin; 4-HNE, 4-hydroxyalkenals; LV, left ventricle; MDA, malondialdehyde; NMCM, neonatal cardiomyocytes; LDH, lactate dehydrogenase; MPO, myeloperoxidase; AS-ODN, antisense deoxyoligonucleotide; MMP, matrix metalloproteinase; qPCR, quantitative PCR.

FIGURE 1. Reperfusion (R) following 30 min of ischemia (I) induces TRAF3IP2 expression in the heart. A, sham operation fails to induce TRAF3IP2 expression. Control mice underwent sham operation. TRAF3IP2 expression was analyzed in LV tissue by immunoblotting. LV tissue from naïve animals served as controls. Numbers at the top denote individual animals. B, I/R up-regulates TRAF3IP2 expression. Control mice underwent 30 min ischemia and reperfusion for up to 6 h. Details of the I/R protocol are shown on the left. TRAF3IP2 expression in the ischemic zones was analyzed by immunoblotting, and a representative immunoblot is shown. Sham-operated (S) and ischemia (I) alone groups served as controls. Intensity of immunoreactive bands from 5 to 6 animals was quantified by densitometry and summarized at the bottom. ⋆, p < 0.01 versus Sham or Ischemia alone. C, localization of TRAF3IP2 in the heart following 30-min ischemia/2-h reperfusion. TRAF3IP2 expression was localized by immunohistochemistry (Is, ischemic zone; NT, normal tissue). Control IgG: normal mouse IgG2a. Arrows denote positive immunoreactivity.
After having demonstrated that I/R up-regulates TRAF3IP2 expression in the heart (Fig. 1B), and is localized predominantly in cardiomyocytes (Fig. 1C), we next determined whether TRAF3IP2 plays a causal role in I/R-induced myocardial injury, dysfunction, and adverse remodeling. We generated tamoxifen-regulated, cardiomyocyte (CM)-specific Traf3ip2 knockout mice (Cre/H11001/H11002;TRAF3IP2fl/H11001; CM-KO). At 2 months of age, both CM-KO and littermate controls (Cre/H11001/H11002;TRAF3IP2/H11001/H11001) received tamoxifen, and after 1 month, TRAF3IP2 levels were analyzed in the heart. Prior to tamoxifen administration, TRAF3IP2 expression was markedly reduced only in the CM-KO mice (Fig. 2A, left lower panel). Furthermore, whereas TRAF3IP2 expression was readily detectable in both cardiomyocytes (CM) and cardiac fibroblasts isolated from the CM-KO mice without tamoxifen administration, its expression was markedly and selectively attenuated in CM following tamoxifen administration (Fig. 2B, upper panel). However, tamoxifen administration failed to affect TRAF3IP2 expression in non-target organs like lung, liver, and kidneys from the CM-KO mice (Fig. 2C). These results indicate that Traf3ip2 gene deletion was specific to cardiomyocytes.

One month after tamoxifen administration, both control and CM-KO mice underwent 30 min I and 2 or 24 h reperfusion. Sham-operated and ischemia alone groups served as controls. Immunoblotting revealed that whereas I/R up-regulated TRAF3IP2 expression in control mice, its levels were significantly attenuated in the CM-KO group (Fig. 2D). Furthermore, echocardiography revealed that at baseline, the fractional shortening (FS) was similar in both control and CM-KO mice (Fig. 2E). However, FS was reduced to a larger extent after I/R in control (26 ± 3.46%; 55% reduction; Fig. 2F) compared with CM-KO mice (36 ± 4.2%; 21% reduction, Fig. 2F).
Integrins, and this effect generation was quantified by cytochrome

VOLUME 292 • NUMBER 6 • FEBRUARY 10, 2017

Increased oxidative stress plays a key role in the activation of NF-κB and AP-1, both of which regulate the expression of various inflammatory mediators. Because I/R-induced oxidative stress and TRAF3IP2 expression in the heart post-I/R, we next investigated whether Traf3ip2 gene deletion blunts activation of IKK/NF-κB and JNK/AP-1, and induction of inflammatory mediators in the heart post-I/R. Results in Fig. 4A show that although I/R induced activation of IKKβ, p65, JNK, and c-Jun (Fig. 4A), and expression of IL-18, LIX, and ICAM1 (Fig. 4B), these changes were markedly attenuated in the CM-KO mice. Furthermore, RT² Profiler™ PCR Arrays revealed a marked increase in the mRNA expression of chemokines (Ccl2), chemokine receptors (Ccr2 and Ccr3), inflammatory cytokines (IL-1β, IL-6, IL-17A, IL-17F, IL-18, IL-33, and TNF-α), adhesion molecules (ICAM1 and LFA-1), growth factors (TGFβ and CTGF), and matrix metalloproteins (2 and 9), and fibrillar collagens (Ia1 and Ilia1) in control mice, and these effects were markedly attenuated in the CM-KO mice (Table 1).

Having demonstrated that the gene expression of various inflammatory mediators is markedly reduced in hearts from the CM-KO mice following 30-min ischemia/2-h reperfusion (Fig. 4 and Table 1), we next analyzed changes in protein levels of inflammatory mediators at 24-h reperfusion using a Quantibody® Mouse Cytokine Antibody Array that simultaneously detects changes in 200 proteins. Again, the results showed a marked inhibition in the protein levels of various inflammatory mediators (cytokines, chemokines, and adhesion molecules), and MMPs in the CM-KO hearts (Table 2). Furthermore, systemic levels of IL-1β, IL-6, IL-17A, IL-17F, IL-18, IL-33, and TNF-α were also significantly reduced in the CM-KO mice (Fig. 4B). Infarct size was measured after 24 h by TTC staining and planimetry (26). Animals with an area at risk of less than 18% were excluded from the study as these animals had little or no infarct. The mean I/R-induced infarct size of control mice was 46.7% (Fig. 2F). Notably, the I/R-induced infarct size was markedly attenuated in the CM-KO mice (a 71% reduction; Fig. 2F).

These results indicate that Traf3ip2 gene deletion in a conditional cardiomyocyte-specific manner blunts contractile dysfunction and injury post-I/R (Fig. 2). Sustained nitroxidative stress contributes to contractile dysfunction and myocardial injury post-I/R (1, 27–29). Therefore we next determined whether I/R increases nitroxidative stress in the heart, and whether Traf3ip2 gene deletion blunts this response. Both control and CM-KO mice underwent I/R (Fig. 3A). The results show that whereas I/R increases H2O2 production in control mice within 30 min of reperfusion, its levels increased further at 1 h and declined gradually thereafter (Fig. 3A). Traf3ip2 gene deletion significantly reduced this effect (Fig. 3A). Similarly, I/R increased O2− generation, and this effect was also reduced by Traf3ip2 gene deletion (Fig. 3B). Supporting these data, tissue levels of lipid peroxidation products (malondialdehyde (MDA)/4-hydroxyalkenals (4-HNE)) were also markedly increased in hearts from control, but not CM-KO mice post-I/R (Fig. 3C). I/R also significantly increased the inducible form of nitric-oxide synthase (iNOS) in control mice, but to a significantly lesser degree in the CM-KO mice (Fig. 3D).

Similarly, I/R-induced nitrotyrosine levels were also markedly reduced in the CM-KO mice (Fig. 3E). These results indicate that Traf3ip2 gene deletion blunts nitroxidative stress in the heart post-I/R (Fig. 3).

Increased oxidative stress plays a key role in the activation of NF-κB and AP-1, both of which regulate the expression of various inflammatory mediators. Because I/R-induced oxidative stress and TRAF3IP2 expression in the heart post-I/R, we next investigated whether Traf3ip2 gene deletion blunts activation of IKK/NF-κB and JNK/AP-1, and induction of inflammatory mediators in the heart post-I/R. Results in Fig. 4A show that although I/R induced activation of IKKβ, p65, JNK, and c-Jun (Fig. 4A), and expression of IL-18, LIX, and ICAM1 (Fig. 4B), these changes were markedly attenuated in the CM-KO mice. Furthermore, RT² Profiler™ PCR Arrays revealed a marked increase in the mRNA expression of chemokines (Ccl2), chemokine receptors (Ccr2 and Ccr3), inflammatory cytokines (IL-1β, IL-6, IL-17A, IL-17F, IL-18, IL-33, and TNF-α), adhesion molecules (ICAM1 and LFA-1), growth factors (TGFβ and CTGF), and matrix metalloproteins (2 and 9), and fibrillar collagens (Ia1 and Ilia1) in control mice, and these effects were markedly attenuated in the CM-KO mice (Table 1).

Having demonstrated that the gene expression of various inflammatory mediators is markedly reduced in hearts from the CM-KO mice following 30-min ischemia/2-h reperfusion (Fig. 4 and Table 1), we next analyzed changes in protein levels of inflammatory mediators at 24-h reperfusion using a Quantibody® Mouse Cytokine Antibody Array that simultaneously detects changes in 200 proteins. Again, the results showed a marked inhibition in the protein levels of various inflammatory mediators (cytokines, chemokines, and adhesion molecules), and MMPs in the CM-KO hearts (Table 2). Furthermore, systemic levels of IL-1β, IL-6, IL-17A, IL-17F, IL-18, IL-33, and TNF-α were also significantly reduced in the CM-KO mice (Fig. 4B). Infarct size was measured after 24 h by TTC staining and planimetry (26). Animals with an area at risk of less than 18% were excluded from the study as these animals had little or no infarct. The mean I/R-induced infarct size of control mice was 46.7% (Fig. 2F). Notably, the I/R-induced infarct size was markedly attenuated in the CM-KO mice (a 71% reduction; Fig. 2F).

These results indicate that Traf3ip2 gene deletion in a conditional cardiomyocyte-specific manner blunts contractile dysfunction and injury post-I/R (Fig. 2). Sustained nitroxidative stress contributes to contractile dysfunction and myocardial injury post-I/R (1, 27–29). Therefore we next determined whether I/R increases nitroxidative stress in the heart, and whether Traf3ip2 gene deletion blunts this response. Both control and CM-KO mice underwent I/R (Fig. 3A). The results show that whereas I/R increases H2O2 production in control mice within 30 min of reperfusion, its levels increased further at 1 h and declined gradually thereafter (Fig. 3A). Traf3ip2 gene deletion significantly reduced this effect (Fig. 3A). Similarly, I/R increased O2− generation, and this effect was also reduced by Traf3ip2 gene deletion (Fig. 3B). Supporting these data, tissue levels of lipid peroxidation products (malondialdehyde (MDA)/4-hydroxyalkenals (4-HNE)) were also markedly increased in hearts from control, but not CM-KO mice post-I/R (Fig. 3C). I/R also significantly increased the inducible form of nitric-oxide synthase (iNOS) in control mice, but to a significantly lesser degree in the CM-KO mice (Fig. 3D).

Similarly, I/R-induced nitrotyrosine levels were also markedly reduced in the CM-KO mice (Fig. 3E). These results indicate that Traf3ip2 gene deletion blunts nitroxidative stress in the heart post-I/R (Fig. 3).
Traf3ip2 gene deletion also attenuated tissue myeloperoxidase (MPO) activity, a surrogate marker for neutrophils, in the heart post-I/R (Fig. 4D).

**Traf3ip2 Gene Deletion Attenuates Adverse Myocardial Remodeling**—Restoring blood flow in time to the ischemic region, whereas helping to regain function, also induces oxidative stress and intense inflammation, which can result in cardiomyocyte death (1). Oxidative stress and proinflammatory cytokines contribute to cardiac remodeling (30–32), characterized by increased fibrosis, hypertrophy of surviving cardiomyocytes, myocardial hypertrophy, and transition to heart failure. Because Traf3ip2 gene deletion significantly reduced myocardial oxidative stress, inflammation and injury post-I/R, we next determined whether its gene deletion also inhibits I/R-induced adverse myocardial remodeling and transition to failure. Because myocardial remodeling is a progressive process, which continues long after the initial cardiomyocyte injury and loss, and is an important predictor of heart failure development, we performed cross-sectional studies and analyzed myocardial function at 2, 4, 8, and 12 weeks post-I/R by echocardiography in both control and CM-KO mice. The data revealed a gradual deterioration in contractile function (increased LVIDs and LV Vols) with concomitant decrease in LVPWs and FS, suggesting possible onset of heart failure in control mice at 12 weeks post-I/R (Fig. 5A). Furthermore, increased cardiomyocyte cross-sectional area (Fig. 5B), MMP2 and -9 activities (Fig. 5C), and perivascular and interstitial fibrosis (Fig. 5D) were observed in the non-ischemic region of hearts at 12 weeks post-I/R in control mice. However, these changes were markedly attenuated in the CM-KO mice, demonstrating that targeting TRAF3IP2 is cardioprotective, and attenuates I/R-induced adverse myocardial remodeling (Fig. 5).

**UTMD-mediated Delivery of Phosphorothioated Antisense Deoxynucleotides (AS-ODN) Targeting TRAF3IP2 Is Highly Effective in Attenuating I/R-induced Myocardial Injury**—Because Traf3ip2 gene deletion is cardioprotective following I/R (Fig. 2F), we next determined whether targeting TRAF3IP2 using an interventional approach could inhibit I/R-induced myocardial injury. Because no pharmacological inhibitors specific for TRAF3IP2 were available, we used a phosphorothioated AS-ODN strategy. We had successfully used this strategy before, where we demonstrated that delivery of phos-
TABLE 1
Conditional cardiomyocyte-specific Traf3ip2 gene deletion significantly attenuated I/R-induced inflammatory and extracellular matrix genes

| Inflammation | I/R vs sham; fold-change |
|--------------|--------------------------|
| Control      | CM-KO                    |
| Ccl2 (MCP-1) | 2.5 ± 0.80               | 1.20 ± 0.12*            |
| Ccl6         | 2.2 ± 0.32               | 0.81 ± 0.09*            |
| Ccl9 (MIP1g) | 3.9 ± 0.98               | 1.22 ± 0.14*            |
| Ccl11        | 6.8 ± 1.12               | 2.43 ± 0.32*            |
| Ccl2 (MCP-1-R) | 3.8 ± 0.92          | 0.80 ± 0.04*            |
| Ccr3 (F4/80) | 2.9 ± 0.78               | 1.10 ± 0.01             |
| Ccr5         | 3.13 ± 1.12              | 0.78 ± 0.03*            |
| Ccxl5 (LIX)  | 3.98 ± 0.83              | 1.12 ± 0.12             |
| Il1b         | 2.31 ± 0.71              | 0.81 ± 0.04*            |
| Il10a        | 0.95 ± 0.32              | 0.78 ± 0.04             |
| Il17a        | 2.11 ± 0.89              | 3.18 ± 1.12             |
| Il17f        | 1.98 ± 0.31              | 0.43 ± 0.24             |
| Il6          | 3.24 ± 0.32              | 1.18 ± 0.32             |
| Ilgfb2       | 2.9 ± 0.71               | 1.89 ± 0.51             |
| Mif          | 1.9 ± 0.18               | 0.62 ± 0.12             |
| Pif         | 1.2 ± 0.08               | 0.81 ± 0.02             |
| Tgfb1        | 3.1 ± 0.24               | 1.78 ± 0.13             |
| Tnfa         | 2.98 ± 0.23              | 1.12 ± 0.32             |
| Tnfifs1a     | 2.0 ± 0.18               | 0.32 ± 0.01             |

| Extracellular matrix | |
|----------------------|------------------|
| Cdh3                 | 8.3 ± 0.32       | 3.10 ± 0.56*         |
| Col1a4               | 2.9 ± 0.24       | 0.78 ± 0.09*         |
| Col3a1               | 1.8 ± 0.21       | 0.41 ± 0.07*         |
| Col5a1               | 8.1 ± 1.12       | 2.31 ± 0.02*         |
| Ctf7f                | 5.1 ± 0.91       | 2.14 ± 0.91*         |
| Ctnna1               | 0.12 ± 0.01      | 0.08 ± 0.03          |
| Emcn1                | 2.3 ± 0.26       | 1.12 ± 0.02          |
| Emlin1               | 2.1 ± 0.31       | 1.08 ± 0.32          |
| Fln1                 | 7.3 ± 1.11       | 2.31 ± 0.54*         |
| Igal4                | 1.2 ± 0.32       | 0.07 ± 0.01*         |
| Igal5                | 2.8 ± 0.78       | 1.12 ± 0.49          |
| IgalD                | 0.2 ± 0.01       | 0.12 ± 0.01          |
| Iglb1                | 0.8 ± 0.12       | 0.04 ± 0.01*         |
| Iglb2                | 2.1 ± 0.42       | 1.11 ± 0.03          |
| Mmp2                 | 2.3 ± 0.14       | 0.71 ± 0.02*         |
| Mmp9                 | 2.1 ± 0.26       | 0.32 ± 0.02*         |
| Thbs2                | 3.2 ± 0.21       | 1.32 ± 0.02*         |
| Tnc                  | 21.1 ± 1.19      | 13.8 ± 0.12*         |

| RT-qPCR | |
|---------|------------------|
| Il6     | 3.1 ± 0.39       | 1.2 ± 0.32*         |
| Il6R (IL-6RA) | 4.2 ± 0.78 | 2.3 ± 0.21*         |
| Il6ST (gp130) | 3.7 ± 0.91  | 1.9 ± 0.13*         |
| Il18    | 3.4 ± 0.32       | 0.78 ± 0.21*         |
| Cc12 (MIP-2a) | 2.39 ± 0.18 | 1.12 ± 0.31         |
| Igal (LFA-1) | 3.0 ± 0.71  | 1.19 ± 0.12          |
| Icam1   | 2.9 ± 0.21       | 1.23 ± 0.21*         |

* p at least 0.05 versus control.

phosphorothioated AS-ODN against TNF-α encapsulated in PESDA (perfluorocarbon-exposed sonicated dextron albumin) microbubbles into the LV chamber and their release by therapeutic ultrasound (ultrasound-targeted microbubble destruction or UTMD), significantly attenuated I/R-induced TNF-α expression in the heart (33). Using a similar approach, here we targeted Traf3ip2 to determine whether inhibition of Traf3ip2 reduces myocardial injury post-I/R, and whether Traf3ip2 is a better therapeutic target than its downstream effectors NF-κBp65 and JNK in reducing myocardial injury post-I/R.

The AS-ODN against p65 and JNK1 have been described previously (34, 35). To target Traf3ip2, we designed 4 individual AS-ODNs (Table 3; Integrated DNA Technologies), which we first tested for efficacy in vitro by transfection into neonatal mouse cardiomyocytes. Inhibition of target protein expression was confirmed by immunoblotting. Control or scrambled ODN served as non-targeting controls. Transfection with phosphorothioated AS-ODN against p65 markedly attenuated basal p65 levels (Fig. 6A, left panel) without affecting the expression of JNK1, used as off-target control. Similarly, JNK1 AS-ODN attenuated JNK1, but not p65 expression (Fig. 6A, right panel). All four Traf3ip2 AS-ODN efficiently inhibited basal Traf3ip2 expression; however, Oligo#4 appeared to be the
TRAF3IP2 in Ischemic Heart Disease

FIGURE 5. Conditional, cardiomyocyte-specific Traf3ip2 gene deletion attenuates I/R-induced adverse myocardial remodeling. A, Traf3ip2 gene deletion blunts progression of I/R-contractile dysfunction and progression to heart failure. Following 30 min ischemia and reperfusion for up to 12 weeks, myocardial function was analyzed by echocardiography. LVd, Left ventricular internal dimension at end-systole; LV Vol, LV volume; LVPW, left ventricular posterior wall thickness at end-systole. *, p < at least 0.05 versus control-I/R (n = 5–6/group). B, Traf3ip2 gene deletion attenuates development of hypertrophy in the non-ischemic zone. Cardiomyocyte cross-sectional area after a 12-week reperfusion was analyzed in H&E-stained sections by ImageJ software. Although representative images are shown on the left, the mean area was quantified and summarized on the right. *, p < 0.001 versus control-I/R (n = 5–6 animals/group, 100 cells/animal). C, Traf3ip2 gene deletion attenuates I/R-induced MMP2 and MMP9 activation. After indicated reperfusion periods, non-ischemic zones were analyzed for MMP activation by immunoblotting using antibodies that detect both pro and active forms. D, Traf3ip2 gene deletion attenuates I/R-induced fibrosis. After a 12-week reperfusion, fibrosis in non-ischemic zones was analyzed by Picrosirius Red staining. Although representative images are shown on the left, mean collagen positive area is summarized on the right (n = 5–6/group). *, p < at least 0.05 versus respective sham-operated group; †, p < 0.05 versus control-I/R.

TABLE 3
Sequence of phosphorothioated AS-ODN against p65, JNK1, and TRAF3IP2

| Target  | ODN      | ODN sequence | Length |
|---------|----------|--------------|--------|
| p65     | AS       | 5'-G*C*A*A*C*A'G*C*A'T*C*G*T*C*C*A*G*T*G*G*G*C-3' | 19     |
| JNK1    | Scrambled| 5'-G*C*A*A*C*A'G*C*A'T*C*G*T*C*C*A*G*T*G*G*G*C-3' | 19     |
| TRAF3IP2| AS       | 5'-G*C*A*A*C*A'G*C*A'T*C*G*T*C*C*A*G*T*G*G*G*C-3' | 20     |
|         | Control  | 5'-C*G*C*C*G*C*T*C*T*C*T*C*C*T*C*T*C*C*T*C*C*T*C*C*T*C*C*C*G*T*G*G*G*C-3' | 20     |
| Oligo#1-AS | 5'-G*C*A*A*C*A'G*C*A'T*C*G*T*C*C*A*G*T*G*G*G*C-3' | molecular mass: 6229.0 Da; 3' end position: 2023 |
| Oligo#2-AS | 5'-G*C*A*A*C*A'G*C*A'T*C*G*T*C*C*A*G*T*G*G*G*C-3' | molecular mass: 6574.3 Da; 3' end position: 2022 |
| Oligo#3-AS | 5'-G*C*A*A*C*A'G*C*A'T*C*G*T*C*C*A*G*T*G*G*G*C-3' | molecular mass: 6558.3 Da; 3' end position: 2023 |
| Oligo#4-AS | 5'-G*C*A*A*C*A'G*C*A'T*C*G*T*C*C*A*G*T*G*G*G*C-3' | molecular mass: 6558.3 Da; 3' end position: 2023 |
| Oligo#4-scrambled | 5'-A*G*C*A*A*C*A'G*C*A'T*C*G*T*C*C*A*G*T*G*G*G*C-3' | molecular mass: 6558.3 Da; 3' end position: 2023 |

*p65, the p65 subunit of NF-κB; JNK1, c-Jun N-terminal kinase 1; TRAF3IP2, TRAF3 interacting protein 2; asterisk represents phosphorothioated.

most effective (Fig. 6B). The scrambled ODN containing the same nucleotides, but rearranged randomly, did not affect Traf3ip2 expression (Fig. 6B, middle panel). ASK1, IKKβ, JNK1, and Akt served as off-targets, and Traf3ip2 Oligo#4, as well as the scrambled ODN had no effect on their basal expression (Fig. 6C). Notably, Traf3ip2 AS-ODN was highly effective in inhibiting hypoxia/reoxygenation (H/R)-induced cardiomyocyte injury, as evidenced by reduced lactate dehydrogenase (LDH) release (Fig. 6D), caspase-3 activation (Fig. 6E, left panel), and cleaved poly(ADP-ribose) polymerase levels (Fig. 6E, right panel).

Having demonstrated the efficacy of Traf3ip2 AS-ODN#4 in vitro (Fig. 6D), we then investigated its ability in reducing myocardial I/R injury (infarct size) in vivo, and compared it with targeting p65 or JNK1 alone. PESDA alone or PESDA + scrambled ODN served as controls. Infarct size was quantified after 24 h as in Fig. 2E. The results showed that 30-min ischemia/24-h reperfusion (Fig. 7A) induced significant injury (increased infarct size; injured areas are indicated by white arrows), and administration of control AS-ODN had no detectable effect on this outcome (Fig. 7B). In contrast, p65 and JNK1 AS-ODN each attenuated infarct size between 40 and 44% (Fig. 7B); how-
TRAF3IP2 in Ischemic Heart Disease

**FIGURE 6. TRAF3IP2 AS-ODN attenuated hypoxia/reoxygenation (H/R)-induced cardiomyocyte injury in vitro.** A, phosphorothioated p65 AS-ODN (p65 AS) attenuated basal p65 expression in NMCM. A representative immunoblot showing reduced p65 expression in NMCM transfected with p65 AS-ODN (500 nM; left panel). Likewise, phosphorothioated JNK1 AS-ODN (JNK1 AS; 500 nM) attenuated basal JNK1 expression in NMCM (right panel). B, phosphorothioated TRAF3IP2 AS-ODN#4 (500 nM), but not its scrambled ODN, attenuated basal TRAF3IP2 expression in NMCM (right panel). NMCM were transfected with 1 of 4 different AS-ODN (500 nM), and analyzed for TRAF3IP2 expression by immunoblotting. Densitometric analysis from three independent experiments is summarized at the bottom. C, untransfected controls. C, TRAF3IP2 AS-ODN#4 or the scrambled ODN had no off-target effects. Transfection with AS-ODN#4 or scrambled ODN affected ASK1, IKK, JNK, nor Akt at basal conditions. D and E, TRAF3IP2 (versus p65 or JNK1) AS-ODN is highly effective in attenuating H/R-induced neonatal cardiomyocyte injury. NMCM transfected with AS-ODN against TRAF3IP2, p65, or JNK1 were exposed to H/R. LDH release into culture supernatant (D), and cleaved caspase-3 and poly(ADP-ribose) polymerase (PARP) levels (E) were analyzed by a colorimetric assay (D) and immunoblotting (E). Normoxia (N) and hypoxia alone (H) served as controls. *, p < 0.01 versus respective scrambled or control AS-ODN; †, p < at least 0.02 versus H/R (n = 12/group).

However, TRAF3IP2 AS-ODN appeared to be most effective at reducing infarct size (Fig. 7B). Neither PESDA alone nor PESDA + scrambled ODN modulated I/R-induced myocardial injury (Fig. 7B). Moreover, each of these AS-ODNs markedly suppressed their target protein expression (Fig. 7C-E). However, the control ODN failed to modulate I/R-induced TRAF3IP2, p65 or JNK1 expression (Fig. 7, C–E). Similar to control ODN, the scrambled ODN also failed to affect I/R-induced myocardial injury (Fig. 8A). Importantly, the TRAF3IP2 AS-ODN, whereas inhibiting TRAF3IP2 expression in the heart, failed to affect its expression in lung, liver, or kidney (Fig. 8B). Furthermore, no histological changes were observed in those non-cardiac organs (Fig. 8C). Liver function also remained unchanged as evidenced by similar levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in serum (Fig. 8D). Together, these results demonstrate that UTMD-mediated delivery of phosphorothioated AS-ODN against TRAF3IP2 into the LV in a clinically relevant time frame markedly inhibits I/R-induced TRAF3IP2 expression, myocardial injury (smaller infarct), and adverse remodeling.

**Discussion**

The major findings of this study are: (i) I/R up-regulates TRAF3IP2 expression in the heart, and (ii) Traf3ip2 gene deletion in a conditional cardiomyocyte-specific manner suppresses I/R-induced nitrooxidative stress, inflammatory response, myocardial dysfunction, injury and adverse remodeling. (iii) Targeting TRAF3IP2 by UTMD-mediated delivery of phosphorothioated AS-ODN markedly attenuates myocardial I/R injury, and (iv) TRAF3IP2 appears to be a better target than its downstream signaling intermediates NF-κB and JNK in reducing I/R injury. Together, the results from these genetic and clinically relevant interventional studies demonstrate that TRAF3IP2 could be a potential therapeutic target in myocardial injury and adverse remodeling post-I/R.

Myocardial I/R injury is a multifactorial disease. Factors, including increased nitrooxidative stress, inflammation, intracellular Ca²⁺ overload, shift in pH, opening of mitochondrial permeability transition pore, endothelial dysfunction, microvascular injury, and altered metabolism, all acting in concert contribute to its pathogenesis (1, 28). Because TRAF3IP2 is an oxidative stress responsive adapter molecule and a critical intermediate in inflammatory signaling (17, 19, 20), we focused mainly on oxidative stress and inflammation. Our results show that I/R markedly increased oxygen-free radical production (H₂O₂ and O₂⁻) in the heart, resulting in increased lipid peroxidation as evidenced by higher levels of MDA and 4-HNE levels, and Traf3ip2 gene deletion attenuated these deleterious effects. Although several oxidoreductases have been identified in the post-ischemic heart, activation of the NADPH oxidases Nox4 and Cybb (Nox2) contribute to H₂O₂ and O₂⁻ generation. Interestingly, Nox4 and Nox2 are NF-κB, AP-1, or IRF1 responsive genes (36–38). Because TRAF3IP2 is an upstream regulator of these transcription factors (18, 19), it is highly likely that Traf3ip2 gene deletion might have resulted in reduced expres-
We have also shown that Traf3ip2 gene deletion inhibited Nos2 expression, also a NF-κB-responsive gene (39), in the heart post-I/R. This was accompanied by reduced levels of nitrotyrosine, a surrogate marker of peroxynitrite. Peroxynitrite is a potent pro-oxidant formed by the reaction between O₂⁻ and NO, and is a known mediator of reperfusion injury (29, 40). It is thus possible that Traf3ip2 gene deletion might have resulted in reduced infarct size due to inhibition of nitroxidative stress in the heart post-I/R.

Of note, both oxidative stress and nitrative stress contribute to inflammation and injury, and Traf3ip2 gene deletion inhibited the expression of multiple inflammatory mediators, including IL-1β, IL-6, IL-17, IL-18, and TNF-α in the heart post-I/R. Traf3ip2 gene deletion also blunted I/R-induced increases in MPO activity, a surrogate marker of neutrophil infiltration. Traf3ip2 gene deletion also attenuated the expres-
sion of adhesion molecule ICAM-1 and LFA-1, both of which play a role in neutrophil adhesion to endothelial cells and subsequent extravasation. Because several of these inflammatory mediators are known negative myocardial inotropes, it is highly likely that reduced expression of cytokines, chemokines, and adhesion molecules might have contributed to reduced inflammatory cell infiltration, improved function, and smaller infarct in the Traf3ip2 knockout mice.

Analogous to the results obtained in the CM-KO mice, UTMD-mediated delivery of phosphorothioated Traf3ip2 AS-ODN in a clinically relevant time frame (during reperfusion) markedly attenuated myocardial I/R injury. Although targeting p65 and JNK1 each attenuated the infarct size between 40 and 44%, targeting Traf3ip2 was highly effective and reduced the infarct size by a significant 61%. Interestingly, whereas inhibiting Traf3ip2 expression in the heart, administration of Traf3ip2 AS-ODN did not affect Traf3ip2 expression in non-target organs like lung, liver, and kidney. Furthermore, no histological changes were observed in these non-target organs, indicating that targeted delivery of AS-ODN to the heart can safely and effectively reduce myocardial injury post-I/R, and without adversely affecting other major organs. These results suggest that UTMD-mediated delivery of Traf3ip2 AS-ODN in a clinically relevant time frame is a viable therapeutic approach in ischemic heart disease.

Although the exact mechanism of ultrasound-mediated transfection is not fully known, several possibilities have been discussed. For example, therapeutic ultrasound may enhance AS-ODN entry into cells by increasing vascular endothelial disruption in the target organ, facilitating passage between cells and across the microvascular barrier (42–45). It is also possible that destabilization and microporation of cell membranes might enhance AS-ODN uptake. Importantly, the membrane damage was shown to be reversible, with resealing of holes (46). Moreover, UTMD increases uptake of the therapeutic agent by 10–12-fold in the heart (45). Mukherjee et al. (47) have previously reported endothelial membrane disruption, pore formation, and increased intercellular gaps in rat hearts following ultrasound application with acoustic power in the range between 0.8 and 1.0 W/cm². These authors also observed no structural changes with a power of 0.6 W/cm², as used in this study (47). Of note, UTMD is now being used in larger animals, including pigs, to deliver viral vectors, drugs, and DNA (48). Therefore, UTMD-mediated delivery of AS-ODN may be a viable therapeutic approach in ischemic heart disease.

We have demonstrated that targeting Traf3ip2 reduces activation of IKK, NF-κB, JNK, and AP-1 in the heart post-I/R. It is well established that activation of IKK and NF-κB is detrimental in I/R injury. For example, Nfkb1 (the p50 subunit of the NF-κB dimer) gene deletion inhibited I/R-induced NF-κB activation and myocardial injury (49). Administration of Bay 65-1942, an ATP-competitive inhibitor that selectively targets IKK β kinase activity significantly reduced NF-κB activation, inflammatory cytokine expression, and myocardial injury post-I/R (8). Another major downstream target of Traf3ip2 is JNK. Interestingly, ischemia alone promotes Jnk1 nuclear translocation, but not activation (50). However, reperfusion results in its activation (50), possibly due to increased reactive oxygen species generation during the initial stages of reperfusion. It has also been shown that I/R induces JNK activation, preferentially the 55-kDa isoform (JNK1) both in vitro and in vivo (10). Importantly, administration of a peptide inhibitor that specifically targets JNK reduced I/R injury ex vivo (12). Furthermore, genetic ablation of jnk1 or jnk2, or transgenic overexpression of a dominant-negative mutant form of JNK1/2 resulted in reduced basal JNK activity, I/R-induced cardiomyocyte death and myocardial injury (11). Here we have demonstrated that targeting NF-κBp65 or JNK1 by UTMD-mediated delivery of AS-ODN markedly reduces myocardial injury post-I/R, and Traf3ip2 appears to be a better therapeutic target compared with p65 or JNK1 alone, possibly due to suppression of pro-inflammatory and/or pro-death pathways regulated by both IKK/NF-κB and JNK/AP-1 in the heart post-I/R. It is also possible that targeting Traf3ip2 might have blocked amplification of inflammatory pathways by inhibiting the cross-talk between IKK and JNK, resulting ultimately in reduced myocardial injury.

In addition to activation of critical signaling intermediates like IKK/NF-κB and JNK/AP-1, induction of Traf3ip2 is also known to activate the mitogen-activated protein kinase p38 (p38 MAPK). Activation of p38 MAPK induces the expression of various inflammatory mediators in part via NF-κB- and/or AP-1-dependent signaling. Importantly, inhibition of p38 MAPK suppresses cardiomyocyte death and improves myocardial function post-I/R (51). Targeting p38 MAPK also reduces I/R-induced endothelial adhesion molecule expression, neutrophil infiltration, and myocardial injury. Therefore, it is highly likely that suppression of p38 MAPK activation might have also contributed to reduced myocardial injury post-I/R in CM-KO mice and following UTMD-mediated delivery of Traf3ip2 AS-ODN in wild type mice. Thus, Traf3ip2 could be a potential therapeutic target in ischemic heart disease.

Future Perspectives—Unlike its causal role in the I/R injury (49), activation of NF-κB is cardioprotective in the MI (permanent ligation of coronary artery) model (52). However, JNK activation plays a deleterious role in both I/R (11, 12) and MI (53) models. Because Traf3ip2 is an upstream regulator of both NF-κB and JNK, it will be critical to determine whether targeting Traf3ip2 reduces myocardial injury and adverse remodeling post-MI.

Experimental Procedures

Animals and Generation of Conditional Cardiomyocyte-specific Traf3ip2 Knock-out Mice—All animal studies conformed to NIH guidelines, and were approved by the Institutional Animal Care and Use Committees at Tulane University, New Orleans, LA, and University of Texas Health Sciences Center, San Antonio, TX. Generation of Traf3ip2-loxP targeted mice (exon 2 was flanked by loxp sites; floxed or fl) on a C57Bl/6 background was previously described (54). The floxed mice were crossed with αMHC-MerCreMer mice (stock number 005650; The Jackson Laboratory) to generate Cre<sup>+/−</sup>; Traf3ip2<sup>fl/−</sup> (CM-Traf3ip2-KO or CM-KO) mice. Two-month-old male CM-KO mice were injected with tamoxifen in corn oil (Sigma, 20 mg/kg body wt, IP) daily for 4 days to delete Traf3ip2 specifically in cardiomyocytes. As experimental
controls, we used two genotypes: Cre<sup>−/−</sup>;TRAF3IP2<sup>fl/fl</sup> and Cre<sup>+/+</sup> mice. All the animals were injected with tamoxifen and Cre<sup>−/−</sup>;TRAF3IP2<sup>+/+</sup> mice were used to confirm that the observed phenotype was not due to loxP insertion into the TRAF3IP2 allele, and Cre<sup>+/+</sup>;TRAF3IP2<sup>+/+</sup> mice were used to confirm that Cre expression was not the cause of the phenotype. One month after the last tamoxifen injection, TRAF3IP2 expression in LV tissue from control and CM-KO mice was analyzed by immunoblotting. Hearts from the two control groups and WT mice appeared normal by histology, and were similar to hearts from untreated naive mice (data not shown). Therefore, in all subsequent experiments, we used Cre<sup>−/−</sup> mice as controls. One month after the last tamoxifen administration, both control and CM-KO mice underwent the I/R procedure as previously described (26) using a chronically instrumented closed chest mouse model. The animal numbers are detailed in Tables 4 and 5. A subgroup of animals underwent ischemia only (30 min ischemia and no reperfusion). Sham-operated animals were prepared identically, but without ligation of the left anterior descending coronary artery. At the indicated time points, the hearts were rapidly excised and rinsed in ice-cold physiological saline. The right ventricle and atria were trimmed away, and the left ventricle was divided into ischemic and non-ischemic zones and snap frozen in liquid N<sub>2</sub> and stored at −80 °C.

**UTMD-mediated AS-ODN Delivery**—PESDA is an echocardiographic contrast agent, and retains the drug binding properties of albumin site 1 and the ability to bind AS-ODN with high affinity (55). The delivery system takes advantage of both the drug binding properties of PESDA and the fact that PESDA microbubbles can be destroyed with ultrasound (56). UTMD can release ODNs locally in high concentration, resulting in fewer side effects. The phosphorothioate internucleotide linkages increase endo- and exonuclease resistance in vivo. Preparation of PESDA microbubbles, encapsulation of phosphorothioated AS-ODN (100 μg), arterial delivery into LV, and application of ultrasound, have all been described in detail previously (33). PESDA microbubbles were prepared on the day of experiment and used within 4 h. AS-ODN mixed with PESDA was infused arterially into anesthetized wild type mice using a small silastic catheter (Micro-Renathane, Braintree Scientific, Inc., Braintree MA) advanced into the LV via the right carotid artery. The animals then underwent 30 min ischemia. During the reperfusion period, PESDA microbubbles with AS-ODN were delivered slowly over a period of 10 min with simultaneous application of therapeutic ultrasound to the anterior chest wall (1 MHz, 0.6 W/cm<sup>2</sup>, 500 mm<sup>2</sup> applicator, 15 min; Sonicator<sup>®</sup> 730, Mettler Electronics Corp., Anaheim, CA) as described previously in rats (33). After treatment, the catheter was removed, the artery ligated, and the animals allowed to recover. No cell death was observed in WT mice that underwent UTMD (no changes in cardiac troponin I levels and TUNEL-positive cells) (6).

**Echocardiography, Infarct Size Measurement, Cardiomyocyte Size, and Fibrosis**—FS was calculated from M-mode images taken in short axis view at the level of the papillary muscles using a Vevo 770 high-resolution ultrasound system (FUJIFILM VisualSonics, Toronto, ON) with a 30-MHz frequency real-time microvisualization scan head (RMV707). FS was calculated using the equation %FS = LVEDD − LVESD/LVEDD × 100, where LVEDD is LV end diastolic diameter, and LVESD is LV end systolic diameter. Infarct size was quantified after 24 h reperfusion using TTC (26). TTC normally stains tissue dark red; infarcted tissue will be unstained and appear white. The LV area (LV), area at risk (AR), and area of necrosis (AN) for all slices were calculated by planimetry. The AR was expressed as a percentage of LV (percentage of AR = total AR/total LV × 100), and the AN was expressed as a percentage of the AR (infarct size = total AN/total AR × 100). Hearts used for infarct size measurement were not employed in biochemical or molecular analyses. Cardiomyocyte size was determined by measuring the cross-sectional area in H&E-stained sections and quantified using Image<sup>®</sup> software. Cardiac fibrosis was analyzed by picrosirius red staining. For quantitative morphometric analysis, five random sections were electronically scanned into RGB images, which were subsequently analyzed using the Image<sup>®</sup> software, and include both perivascular and interstitial fibrosis (57).

**mRNA Expression and MMP Activation**—Total RNA was isolated from frozen LV tissue using TRIzol reagent (Sigma) and 1 μg of RNA was reverse transcribed into cDNA using a reverse transcription kit (Agilent Technologies). mRNA expression was analyzed by RT<sup>2</sup> Profiler<sup>TM</sup> PCR Arrays from Qiagen (Inflammatory Cytokines & Receptors PCR Array, PAMM-011Z; and Extracellular Matrix & Adhesion Molecule PCR Array, PAMM-0132Z) that simultaneously detect 84 genes each. Expressions of genes that were below detection level and those that did not show a significant difference were excluded from the results in Table 1. mRNA expression of genes that were not included in arrays was analyzed by RT-qPCR using

### Table 4

| Treatment groups using a genetic approach | Group | Model | n  |
|------------------------------------------|-------|-------|----|
| 1. Control-sham-operated                 | 24    |       |    |
| 2. Control-I/R                           | 36    |       |    |
| 3. CM-KO-sham-operated                   | 24    |       |    |
| 4. CM-KO-I/R                             | 36    |       |    |

**Table 5**

| Treatment groups using an interventional approach | Group | Wild type C57Bl/6 mice treatment | n  |
|--------------------------------------------------|-------|----------------------------------|----|
| 1. Sham-operated + ultrasound                    | 8     |                                  |    |
| 2. I/R + no treatment + ultrasound               | 12    |                                  |    |
| 3. I/R + PESDA alone + ultrasound                | 12    |                                  |    |
| 4. I/R + control AS-ODN + ultrasound             | 12    |                                  |    |
| 5. I/R + p65 AS-ODN + ultrasound                | 12    |                                  |    |
| 6. I/R + INK1 AS-ODN + ultrasound                | 12    |                                  |    |
| 7. I/R + TRAF3IP2 AS-ODN + ultrasound            | 12    |                                  |    |
| 8. I/R + scrambled ODN + ultrasound              | 12    |                                  |    |

**TRAF3IP2 in Ischemic Heart Disease**

6. J. M. Erikson, A. J. Valente, S. Mummidiri, H. K. Kandikattu, V. G. DeMarco, S. B. Bender, W. P. Fay, U. Siebenlist, and B. Chandrasekar, unpublished observations.
Applied Biosystems TaqMan™ probes. All data were normalized to corresponding hprt (hypoxanthine phosphoribosyltransferase) levels and analyzed using the 2−ΔΔCT method. Activation of MMP2 and -9 was analyzed by immunoblotting using antibodies that detect both pro and active forms (MMP2, NB200–114G, Novus; MMP9, M9570, Sigma) (58).

Protein Quantibody Array, Western Blot Analysis, ELISA, Immunohistochemistry, and MPO Activity—A Quantibody® Mouse Cytokine Antibody Array 4000 (QAM-CAA-4000; RayBiotech) that detects 200 proteins simultaneously was used to analyze changes in protein expression in LV homogenates (57). Expressions of proteins that were below detection level and those that did not show a significant difference were excluded from the results in Table 2. Preparation of protein homogenates, immunoblotting, and densitometry were performed as described previously (17, 19, 20, 26). The source and concentration of antibodies used in immunoblotting are previously described (17, 19, 20, 26). Anti-iNOS antibodies were from Novus (#NB-300; 1:500). Serum levels of IL-1β (number BMS602), IL-6 (number BMS603/2), IL-17A (number BMS6026), IL-17F (number BMS6020), IL-18 (number BMS618/3), IL-33 (number BMS6025), and TNF-α (number BMS607/3) were analyzed by ELISA (eBioscience). TRAF3IP2 expression was localized by immunohistochemistry using anti-TRAF3IP2 antibodies (1:50; number sc-100647, Santa Cruz Biotechnology, Inc.) (57). Normal mouse IgG2a (number sc-3878; Santa Cruz Biotechnology, Inc.) served as a control. MPO activity in ischemic LV tissue was analyzed by a Lactate Dehydrogenase Activity Assay Kit (Sigma) as described previously (26).

Hydrogen Peroxide (H2O2) Production, Superoxide Generation, Lipid Peroxidation, and Nitrotyrosine Levels—H2O2 production in ischemic zones was analyzed by Amplex Red assay as previously described (59). Superoxide generation was quantified by cytoskeleton e assay as previously described (59). Lipid peroxidation was analyzed using a Lipid Peroxidation Assay Kit (Calbiochem) that quantifies both MDA/4-HNE in LV homogenates (26). Nitrotyrosine levels in cleared tissue homogenates were analyzed by ELISA (60).

Serum ALT and AST Activity—Serum ALT and AST activities were analyzed by the Mouse Alanine Aminotransferase ELISA kit (MAK052) and the Mouse Aspartate Aminotransferase kit (MAK055) from Sigma.

Isolation of Neonatal Cardiomyocytes (NMCM), Hypoxia/Reoxygenation and LDH Assay—Cardiomyocytes were isolated from 1 to 3-day-old neonatal C57BL/6 mice as previously described using enzymatic digestion (61). At 70% confluence, the cells were incubated with in DMEM/M199 medium without fetal bovine serum for 12 h. Hypoxia was induced by replacing the initial culture medium with DMEM without glucose and serum, and flushed with 95% N2 and 5% CO2 for 15 min. The cells were then placed in a modular incubator chamber (Billups Rothenberg, Inc., Del Mar, CA) flushed with 95% N2 and 5% CO2 for 60 min. The sealed chamber was then placed into a 37 °C incubator. After the 4-h hypoxia incubation, the medium was replaced with fresh medium containing 10% serum, and an atmosphere of 95% air and 5% CO2 for reoxygenation. After 8 h, LDH released into medium was quantified. To determine the role of p65, JNK, and TRAF3IP2 in H/R-induced cell injury, cells plated at a density of 2 × 104/cm2 in 30-mm Falcon plates were transfected with the respective AS-ODN (500 nM) using FuGENE 6. After 6 h, cells were washed with serum-free medium, and exposed to H/R as described above. LDH levels were analyzed by Lactate Dehydrogenase Assay Kit (MAK066–1KT) from Sigma.

Statistical Analysis—Data were analyzed using Microsoft Excel, Clampfit (Molecular Device, Sunnyvale, CA), and Origin 7 (OriginLab Corp., Northampton, MA) programs. Normality criteria were evaluated to select the correct parametric or non-parametric test using the Shapiro-Wilk estimator. Because the sample size was small (n = 4–8/group), the test determined that the non-parametric approach should be used to avoid type II errors. Because two groups were used (control and CM-KO), pairwise comparisons were made using the Tukey adjustment. The statistical tests were performed using the software SPSS 23.0.0.1 (Chicago, IL). The overall significance level was set at 0.05. The results are presented as the mean ± S.E.

Author Contributions—B. C. designed the experimental strategy and interpreted the data. J. M. E., A. J. V., S. M., H. K., V. D., S. B. B., and W. P. F. performed experiments. U. S. and H. K. generated TRAF3IP2 floxed mice and conditional cardiomyocyte-specific TRAF3IP2 knockout mice. J. M. E., A. J. V., and B. C. analyzed the data. J. M. E., A. J. V., and B. C. wrote the manuscript.

References

1. Hausenloy, D. J., and Yellon, D. M. (2013) Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J. Clin. Invest. 123, 92–100
2. Turer, A. T., and Hill, J. A. (2010) Pathogenesis of myocardial ischemia-reperfusion injury and rationale for therapy. Am. J. Cardiol. 106, 360–368
3. Entman, M. L., Youker, K. A., Frangogiannis, N., Lakshmmanarayan, V., Nossuli, T., Evans, A., Kurrelmeyer, K., Mann, D. L., and Smith, C. W. (2000) Is inflammation good for the ischemic heart: perspectives beyond the ordinary. Z. Kardiol 89, Suppl. IX, 82–87
4. Jones, W. K., Brown, M., Willhide, M., He, S., and Ren, X. (2005) NF-κB activation in cardiovascular disease: diverse and specific effects of a "general" transcription factor? Cardiovasc. Toxicol. 5, 183–202
5. Dawn, B., Xuan, Y. T., Marian, M., Flaherty, M. P., Murphee, S. S., Smith, T. L., Bolli, R., and Jones, W. K. (2001) Cardiac-specific abrogation of NF-κB activation in mice by transdominant expression of a mutant IκBα. J. Mol. Cell Cardiol. 33, 161–173
6. Kim, Y. S., Kim, J. S., Kwon, J. S., Jeong, M. H., Cho, J. G., Park, J. C., Kang, J. C., and Ahn, Y. (2010) BAY 11–7082, a nuclear factor-κB inhibitor, reduces inflammation and apoptosis in a rat ischemia-reperfusion injury model. Int. Heart J. 51, 348–353
7. Squadrato, F., Deodato, B., Squadrato, G., Seminara, P., Passanti, M., Venuti, F. S., Gacci, M., Minutili, L., Adamo, E. B., Bellomo, M., Marini, R., Galeano, M., Marini, H., and Altavilla, D. (2003) Gene transfer of IκB limits infarct size in a mouse model of myocardial ischemia-reperfusion injury. Lab. Invest. 83, 1097–1104
8. Moss, N. C., Stansfield, W. E., Willis, M. S., Tang, R. H., and Selzman, C. H. (2007) IKKβ inhibition attenuates myocardial injury and dysfunction following acute ischemia-reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 293, H2248–H2253
9. Onai, Y., Suzuki, J., Kakuta, T., Maejima, Y., Haraguchi, G., Fukasawa, H., Muto, S., Itai, A., and Isole, M. (2004) Inhibition of IκB phosphorylation in cardiomyocytes attenuates myocardial ischemia/reperfusion injury. Cardiovasc. Res. 63, 51–59
10. Yin, T., Sandhu, G., Wolfgang, C. D., Burrier, A., Webb, R. L., Rigal, D. F., Hai, T., and Whelan, J. (1997) Tissue-specific pattern of stress kinase

TRAF3IP2 in Ischemic Heart Disease
50. He, H., Li, H. L., Lin, A., and Gottlieb, R. A. (1999) Activation of the JNK pathway is important for cardiomyocyte death in response to simulated ischemia. *Cell Death Differ.* **6**, 987–991

51. Ma, X. L., Kumar, S., Gao, F., Louden, C. S., Lopez, B. L., Christopher, T. A., Wang, C., Lee, J. C., Feuerstein, G. Z., and Yue, T. L. (1999) Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. *Circulation* **99**, 1685–1691

52. Misra, A., Haudek, S. B., Knuefermann, P., Vallejo, J. G., Chen, Z. J., Michael, L. H., Sivasubramanian, N., Olson, E. N., Entman, M. L., and Mann, D. L. (2003) Nuclear factor-κB protects the adult cardiac myocyte against ischemia-induced apoptosis in a murine model of acute myocardial infarction. *Circulation* **108**, 3075–3078

53. Wei, J., Wang, W., Chopra, I., Li, H. F., Dougherty, C. I., Adi, J., Adi, N., Wang, H., and Webster, K. A. (2011) c-Jun N-terminal kinase (JNK-1) confers protection against brief but not extended ischemia during acute myocardial infarction. *J. Biol. Chem.* **286**, 13995–14006

54. Pisitkun, P., Ha, H. L., Wang, H., Claudio, E., Tivy, C. C., Zhou, H., Mayadas, T. N., Illei, G. G., and Siebenlist, U. (2012) Interleukin-17 cytokines are critical in development of fatal lupus glomerulonephritis. *Immunity* **37**, 1104–1115

55. Srinivasan, S. K., Tewary, H. K., and Iversen, P. L. (1995) Characterization of binding sites, extent of binding, and drug interactions of oligonucleotides with albumin. *Antisense Res. Dev.* **5**, 131–139

56. Porter, T. R., Iversen, P. L., Li, S., and Xie, F. (1996) Interaction of diagnostic ultrasound with synthetic oligonucleotide-labeled perfluorocarbon-exposed sonicated dextrose albumin microbubbles. *J. Ultrasound Med.* **15**, 577–584

57. Yarisiwamy, M., Yoshida, T., Valente, A. J., Kandikattu, H. K., Sakamuri, S. S., Siddesha, J. M., Sukhunov, S., Saifudeen, Z., Ma, L., Siebenlist, U., Gardner, J. D., and Chandrasekar, B. (2016) Cardiac-restricted overexpression of TRAF3 interacting protein 2 (TRAF3IP2) results in spontaneous development of myocardial hypertrophy, fibrosis, and dysfunction. *J. Biol. Chem.* **291**, 19425–19436

58. Siddesha, J. M., Valente, A. J., Sakamuri, S. S., Yoshida, T., Gardner, J. D., Somanna, N., Takahashi, C., Noda, M., and Chandrasekar, B. (2013) Angiotensin II stimulates cardiac fibroblast migration via the differential regulation of matrixins and RECK. *J. Mol. Cell Cardiol.* **65**, 9–18

59. Frazziano, G., Al Ghouleh, I., Baust, J., Shiva, S., Champion, H. C., and Pagano, P. J. (2014) Nox-derived ROS are acutely activated in pressure overload pulmonary hypertension: indications for a seminal role for mitochondrial Nox4. *Am. J. Physiol. Heart Circ. Physiol.* **306**, H197–H205

60. Ma, X. L., Gao, F., Nelson, A. H., Lopez, B. L., Christopher, T. A., Yue, T. L., and Barone, F. C. (2001) Oxidative inactivation of nitric oxide and endothelial dysfunction in stroke-prone spontaneous hypertensive rats. *J. Pharmacol. Exp. Ther.* **298**, 879–885

61. Colston, J. T., de la Rosa, S. D., Koehler, M., Gonzales, K., Mestril, R., Freeman, G. L., Bailey, S. R., and Chandrasekar, B. (2007) Wnt-induced secreted protein-1 is a prohypertrophic and profibrotic growth factor. *Am. J. Physiol. Heart Circ. Physiol.* **293**, H1839–H1846

56. Porter, T. R., Iversen, P. L., Li, S., and Xie, F. (1996) Interaction of diagnostic ultrasound with synthetic oligonucleotide-labeled perfluorocarbon-exposed sonicated dextrose albumin microbubbles. *J. Ultrasound Med.* **15**, 577–584

57. Yarisiwamy, M., Yoshida, T., Valente, A. J., Kandikattu, H. K., Sakamuri, S. S., Siddesha, J. M., Sukhunov, S., Saifudeen, Z., Ma, L., Siebenlist, U., Gardner, J. D., and Chandrasekar, B. (2016) Cardiac-restricted overexpression of TRAF3 interacting protein 2 (TRAF3IP2) results in spontaneous development of myocardial hypertrophy, fibrosis, and dysfunction. *J. Biol. Chem.* **291**, 19425–19436

58. Siddesha, J. M., Valente, A. J., Sakamuri, S. S., Yoshida, T., Gardner, J. D., Somanna, N., Takahashi, C., Noda, M., and Chandrasekar, B. (2013) Angiotensin II stimulates cardiac fibroblast migration via the differential regulation of matrixins and RECK. *J. Mol. Cell Cardiol.* **65**, 9–18

59. Frazziano, G., Al Ghouleh, I., Baust, J., Shiva, S., Champion, H. C., and Pagano, P. J. (2014) Nox-derived ROS are acutely activated in pressure overload pulmonary hypertension: indications for a seminal role for mitochondrial Nox4. *Am. J. Physiol. Heart Circ. Physiol.* **306**, H197–H205

60. Ma, X. L., Gao, F., Nelson, A. H., Lopez, B. L., Christopher, T. A., Yue, T. L., and Barone, F. C. (2001) Oxidative inactivation of nitric oxide and endothelial dysfunction in stroke-prone spontaneous hypertensive rats. *J. Pharmacol. Exp. Ther.* **298**, 879–885

61. Colston, J. T., de la Rosa, S. D., Koehler, M., Gonzales, K., Mestril, R., Freeman, G. L., Bailey, S. R., and Chandrasekar, B. (2007) Wnt-induced secreted protein-1 is a prohypertrophic and profibrotic growth factor. *Am. J. Physiol. Heart Circ. Physiol.* **293**, H1839–H1846